权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic predicators of asthma in neonates

新生儿哮喘的表观遗传预测因素

基本信息

批准号：
7935439
负责人：
Donata Vercelli
金额：
$ 47.24万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7935439
关键词：
Address Adult Affect Age Allergens Area Asthma Automobile Driving Biological Markers Birth Blood Cells Blood donor Blood specimen Candidate Disease Gene Child Childhood Asthma CpG dinucleotide DNA Methylation Development Diagnosis Disease Effectiveness Enrollment Epidemic Epigenetic Process Exposure to Future Gene Expression Genes Health Immune Individual Infant Life Measurement Measures Methylation Mothers Nature Neonatal Nursery Schools Pattern Play Population Pregnancy Prevention Preventive Principal Investigator Process Promoter Regions Prospective Studies Quality of life Recurrence Reducing Agents Resolution Reverse Transcriptase Polymerase Chain Reaction Role Sampling Testing Tobacco smoke Umbilical Cord Blood United States Validation Wheezing bisulfite early childhood emerging adult environmental agent genome-wide improved mRNA Expression neonate programs promoter public health relevance research study

项目摘要

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (03) Biomarker discovery and validation, and specific Challenge Topic, 03-OD-101: Use of epigenetic signatures in blood cells to predict disease. Asthma can currently be managed but not really cured. Therefore, prevention would be an ideal approach to this disease. Obviously, availability of asthma predictors detectable in early life, or even better at birth, would greatly improve the effectiveness of prevention by identifying those individuals within the population for whom more drastic, and therefore less easy to implement, preventive measures might be most justified and useful. Because asthma typically begins in early life, and the asthma status of the child is strongly related to that of the mother, the overall hypothesis driving this application is that signatures detectable in the epigenome, and more specifically, in the methylome, at birth can serve as predictors of asthma status later in life. To test this hypothesis, we propose to assess genome-wide patterns of DNA methylation, a robust and quantifiable epigenetic mark. Our analysis will focus on cord blood samples isolated from children enrolled in the longitudinal Infant Immune Study (IIS), and already available. The longitudinal nature of the IIS study offers a unique opportunity to address and answer questions about early epigenetic predictors of asthma. Indeed, the cord blood donors have now reached age 5-8 yrs, an age at which a firm diagnosis of asthma can be established. Results for the most robust candidate genes will be quantitatively validated by bisulfite sequencing and measurements of candidate gene expression levels. Specific Aim 1 To identify candidate epigenetic predictors of asthma by interrogating the methylome of cord blood cells isolated from neonates who have or have not become asthmatic by age 5 yrs. We will perform genome-wide comparisons of promoter DNA methylation patterns in cord blood cells isolated from neonates enrolled in the IIS study (n=20 per group), and we will use asthma status at age 5 yrs to anchor and interpret these results. Each group will contain equal numbers of samples from neonates whose mothers were or were not asthmatic during pregnancy. These experiments will yield candidate epigenetic predictors of asthma, which will be validated in Aim 2. Specific Aim 2 To validate the candidate epigenetic predictors of asthma identified in Aim 1 by using quantitative high resolution bisulfite sequencing and gene expression assessments. We will implement a stringent strategy to filter and further explore the putative epigenetic predictors of asthma identified in Aim 1. Genes found to be differentially methylated by genome-wide promoter methylation arrays (at least 10) will be biologically validated by measuring levels of DNA methylation at promoter regions and individual CpG dinucleotides (by bisulfite sequencing) and levels of mRNA expression (by RT-PCR). These analyses will include the 40 initial samples and 40 additional ones. Genes showing a functionally concordant pattern of differential epigenetic changes and expression (e.g., genes that are more intensely expressed and hypomethylated) correlated with subsequent development of asthma in the child will be considered as bona fide neonatal epigenetic predictors of asthma, and will be proposed for future prospective studies. PUBLIC HEALTH RELEVANCE: This application addresses broad Challenge Area (03) Biomarker discovery and validation, and specific Challenge Topic, 03-OD-101: Use of epigenetic signatures in blood cells to predict disease. Asthma can currently be managed but not really cured. Therefore, prevention would be an ideal approach to this disease. Obviously, availability of asthma predictors detectable in early life, or even better at birth, would greatly improve the effectiveness of prevention by identifying those individuals within the population for whom more drastic, and therefore less easy to implement, preventive measures might be most justified and useful. Because asthma typically begins in early life, and the asthma status of the child is strongly related to that of the mother, the overall hypothesis driving this application is that signatures detectable in the epigenome, and more specifically, in the methylome, at birth can serve as predictors of asthma status later in life. To test this hypothesis, we propose to assess genome-wide patterns of promoter DNA methylation, a robust and quantifiable epigenetic mark. Our analysis will focus on cord blood samples (n=40) isolated from children enrolled in the longitudinal Infant Immune Study (IIS), and already available. The longitudinal nature of the IIS study offers a unique opportunity to address and answer questions about early epigenetic predictors of asthma. Indeed, the cord blood donors have now reached age 5-8 yrs, an age at which a firm diagnosis of asthma can be established. Results for the most robust candidate genes will be quantitatively validated by bisulfite sequencing and measurements of candidate gene expression levels, extending the analysis to 40 additional samples. Genes showing a functionally concordant pattern of differential epigenetic changes and expression (e.g., genes that are more intensely expressed and hypomethylated) correlated with subsequent development of asthma in the child will be considered as bona fide neonatal epigenetic predictors of asthma, and will be proposed for future prospective studies.

描述（由申请人提供）：本申请涉及广泛的挑战领域（03）生物标志物发现和验证，以及特定的挑战主题03-OD-101：使用血细胞中的表观遗传特征预测疾病。哮喘目前可以控制，但不能真正治愈。因此，预防将是治疗这种疾病的理想方法。显然，在生命早期甚至在出生时就可以检测到哮喘预测因子的可用性，将通过识别人群中那些更严厉（因此不太容易实施）的预防措施可能是最合理和最有用的人，大大提高预防的有效性。由于哮喘通常在生命早期开始，并且儿童的哮喘状态与母亲的哮喘状态密切相关，因此驱动该应用的总体假设是，出生时在表观基因组中可检测到的签名，更具体地说，在甲基化组中可作为以后生活中哮喘状态的预测因子。为了验证这一假设，我们建议评估DNA甲基化的全基因组模式，这是一种稳健且可量化的表观遗传标记。我们的分析将集中在从纵向婴儿免疫研究（IIS）中招募的儿童中分离的脐带血样本上，并且已经可用。IIS研究的纵向性质提供了一个独特的机会来解决和回答有关哮喘早期表观遗传预测因子的问题。事实上，脐带血捐献者现在已经到了5-8岁的年龄，在这个年龄可以确定哮喘的诊断。最稳健的候选基因的结果将通过亚硫酸氢盐测序和候选基因表达水平的测量进行定量验证。具体目的1通过对5岁时患或未患哮喘的新生儿分离的脐带血细胞的甲基化组进行分析，确定哮喘的候选表观遗传预测因子。我们将对IIS研究中入选的新生儿分离的脐带血细胞的启动子DNA甲基化模式进行全基因组比较（每组n=20），我们将使用5岁时的哮喘状态来锚和解释这些结果。每组将包含相同数量的新生儿样本，其母亲在妊娠期间患有或不患有哮喘。这些实验将产生哮喘的候选表观遗传预测因子，这将在目标2中得到验证。具体目标2通过使用定量高分辨率亚硫酸氢盐测序和基因表达评估来验证目标1中确定的哮喘的候选表观遗传预测因子。我们将实施严格的策略来筛选和进一步探索目标1中确定的哮喘的推定表观遗传预测因子。通过测量启动子区域和单个CpG二核苷酸的DNA甲基化水平（通过亚硫酸氢盐测序）和mRNA表达水平（通过RT-PCR），对通过全基因组启动子甲基化阵列（至少10个）发现差异甲基化的基因进行生物学验证。这些分析将包括40份初始样本和40份额外样本。表现出差异表观遗传变化和表达的功能一致模式的基因（例如，与儿童随后发生哮喘相关的更强烈表达和低甲基化的基因）将被认为是真正的新生儿哮喘表观遗传学预测因子，并将被提议用于未来的前瞻性研究。公共卫生关系：本申请涉及广泛的挑战领域（03）生物标志物的发现和验证，以及特定的挑战主题，03-OD-101：使用血细胞中的表观遗传特征来预测疾病。哮喘目前可以控制，但不能真正治愈。因此，预防将是治疗这种疾病的理想方法。显然，在生命早期甚至在出生时就可以检测到哮喘预测因子的可用性，将通过识别人群中那些更严厉（因此不太容易实施）的预防措施可能是最合理和最有用的人，大大提高预防的有效性。由于哮喘通常在生命早期开始，并且儿童的哮喘状态与母亲的哮喘状态密切相关，因此驱动该应用的总体假设是，出生时在表观基因组中可检测到的签名，更具体地说，在甲基化组中可作为以后生活中哮喘状态的预测因子。为了验证这一假设，我们建议评估启动子DNA甲基化的全基因组模式，这是一种稳健且可量化的表观遗传标记。我们的分析将集中在脐带血样本（n=40）分离的儿童参加了纵向婴儿免疫研究（IIS），并已可用。IIS研究的纵向性质提供了一个独特的机会来解决和回答有关哮喘早期表观遗传预测因子的问题。事实上，脐带血捐献者现在已经到了5-8岁的年龄，在这个年龄可以确定哮喘的诊断。最稳健的候选基因的结果将通过亚硫酸氢盐测序和候选基因表达水平的测量进行定量验证，将分析扩展到40个额外的样本。表现出差异表观遗传变化和表达的功能一致模式的基因（例如，与儿童随后发生哮喘相关的更强烈表达和低甲基化的基因）将被认为是真正的新生儿哮喘表观遗传学预测因子，并将被提议用于未来的前瞻性研究。